Connect the dots.
We’ve had a taste that hypofractionated breast radiation does not confer a greater risk of late toxicity among patients with connective tissue disease than does conventional fractionation. The same group from NYU is back to delve more into this question. Among 92 patients with a diagnosis of autoimmune disease, and consistent with many landmark trials, those who received hypofractionation actually had far lower odds of acute (OR 0.20) and late (OR 0.13) grade 2-3 toxicity on multivariate analysis. Granted, those with active symptoms and/or on meds were more likely to receive conventional fractionation, it’s pretty clear that strategy doesn’t protect against worse toxicity. | Purswani, Pract Radiat Oncol 2021